SILO PHARMA, INC. Finite-Lived Intangible Asset, Expected Amortization, Year One
SILO PHARMA, INC. (SILO) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $11.75 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-08-13
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $11.75K.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $11.75K.
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $11.75K.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $11.75K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2026-06-30 | $11.75K 10-Q · filed 2026-08-13 |
| 2026-03-31 | $11.75K 10-Q · filed 2026-05-14 |
| 2025-12-31 | $11.75K POS AM · filed 2026-04-14 |
| 2025-09-30 | $11.75K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $11.75K 10-Q · filed 2025-08-13 |
| 2025-03-31 | $12.37K 10-Q · filed 2025-05-09 |
| 2024-12-31 | $12.37K 10-K · filed 2025-03-28 |
| 2024-09-30 | $12.37K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $12.37K 10-Q · filed 2024-08-13 |
| 2018-09-30 | $78.97K 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |